Navigation Links
FDA Provides 510k Clearance for BARRX Medical's HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE)
Date:3/3/2010

SUNNYVALE, Calif., March 3 /PRNewswire/ -- BARRX Medical, Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its HALO90 Ablation Catheter for the treatment of Radiation Proctitis (RP) and Gastric Antral Vascular Ectasia (GAVE).  Both conditions are diseases of the gastrointestinal tract associated with chronic bleeding and the need for blood transfusions.  The HALO90 catheter is used in conjunction with the HALOFLEX and HALO90 Energy Generators during endoscopic procedures to control bleeding in the gastrointestinal tract through the coagulation of affected tissue.  The new 510(k) release is an expansion of the HALO90 catheter's previous indication for use, which includes the treatment of a precancerous condition of the esophagus, known as Barrett's esophagus.

Bleeding associated with radiation proctitis is a common side effect of pelvic radiation therapy.  Affecting approximately 5% of patients treated for cancers of the prostate, ovaries and cervix, chronic bleeding from radiation proctitis may result in the need for transfusions, multiple procedures to control bleeding, and impairment in patient quality of life.

Gastric antral vascular ectasia, also known as "watermelon stomach" due to associated striping of the stomach lining, is a condition of the lower stomach in which the blood vessels that make up the stomach lining become fragile and prone to rupture.  While the cause of GAVE is not well understood, it is often associated with systemic diseases such as liver cirrhosis or autoimmune disorders.  Patients with GAVE typically suffer from chronic anemia due to blood loss.  

The HALO90 catheter offers clinicians a novel, non-surgical, outpatient therapy for control of bleeding in their patients with GAVE and RP, many of whom have failed prior endoscopic interventions and have few remaining options.  As evidenced by its extensively studied use for coagulating tissue in the esophagus, the HALO90 catheter treats a broad area of diseased or bleeding tissue rapidly and achieves a controlled depth of ablation, both of which are important factors in the treatment of these conditions.

About BARRX Medical, Inc.

BARRX Medical, Inc. develops treatment solutions for Barrett's esophagus and other chronic gastroenterological diseases.  Barrett's is a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD.  The company's HALO360 and HALO90 ablation systems, provide a uniform and controlled ablation effect, which removes diseased tissue and allows re-growth of normal cells.

A multi-center randomized, sham-controlled study, published in the New England Journal of Medicine, studied HALO radiofrequency ablation applied in the highest risk Barrett's population (those having dysplasia).  The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and significantly decreased the rate of disease progression and cancer development, as compared to the control group.  In another study (AIM-II) published in Gastrointestinal Endoscopy, 98.4 percent of patients were Barrett's-free after two and a half years of follow-up.

Both HALO systems are cleared by the FDA for use in the U.S. and both have CE Mark for use in Europe.  More than 50,000 procedures have been performed in over 350 hospitals around the world.  Based in Sunnyvale, Calif., BARRX Medical, Inc. was founded in 2000 and is privately-held.  Additional information is available at www.barrx.com.

SOURCE BARRX Medical, Inc.

Back to top

RELATED LINKS
http://www.barrx.com

'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... , ... Beleza Medspa has initiated a new program to assist ... first time that Coolsculpting is being used for for more than just cosmetic purposes. ... meet the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting ... and company to wait until March 2017 for an interest rate increase, according to ... College of Business. , “The Federal Open Market Committee (FOMC) dot charts are of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
Breaking Medicine News(10 mins):